AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

PROVEXIS PLC

Director's Dealing Sep 12, 2019

7862_dirs_2019-09-12_efb886c3-9799-4916-8bdf-c7dfede1b43d.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 1765M

Provexis PLC

12 September 2019

12 September 2019

Provexis plc

("Provexis" or the "Company")

Director / PDMR notification

Provexis, the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient, announces that Ian Ford, CEO and CFO, purchased a total of 5,000,000 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 12 September 2019 at an average price of 0.338 pence per Ordinary Share.

Following this purchase, Mr Ford has a total beneficial interest in 10,000,000 Ordinary Shares, equivalent to 0.50% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them are set out below pursuant to the EU Market Abuse regulation.

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ian Ford (Director and PDMR) - shares acquired on behalf of Mr Ford's children (under the age of 18) who are persons closely associated with Mr Ford

2

Reason for the notification

a)

Position/status

See 1a) above

b)

Initial notification

/ Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PROVEXIS PLC

b)

LEI

21380042E3Y3N9VZ6N48

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of 0.1p each

ISIN: GB00B0923P27

b)

Nature of the transaction

Purchase of ordinary shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
0.33 pence

and

0.345 pence
2,500,000

2,500,000

d)

Aggregated information

- Aggregated volume

- Price

5,000,000 shares

Average price of 0.338 pence per share

e)

Date of the transaction

12 September 2019

f)

Place of the transaction

London Stock Exchange, AIM Market

For further information please contact:

Provexis plc

Dawson Buck, Chairman

Ian Ford, CEO & CFO
Tel:         07490 391888

                [email protected]
Allenby Capital Limited

Nick Naylor / Liz Kirchner
Tel:         020 3328 5656

Notes for editors

About Provexis plc

AIM-listed Provexis is focused on the development, licensing and sales of its proprietary, scientifically-proven Fruitflow® heart-health functional food ingredient.

Provexis was founded in 1999 and is headquartered in Reading, Berkshire.

Provexis shares are traded on the AIM market of the London Stock Exchange under the ticker symbol PXS.

For further information, please visit www.provexis.com and www.fruitflowplus.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHGGUQGBUPBGCP

Talk to a Data Expert

Have a question? We'll get back to you promptly.